There are 2789 resources available
684P - Molecular underpinnings of glandular tropism in metastatic clear cell renal cell carcinoma
Presenter: Eduard Roussel
Session: ePoster Display
685P - Genome-wide association meta-analysis identifies novel variants that correlate with efficacy outcomes in sunitinib-treated patients with metastatic renal cell carcinoma
Presenter: Meta Diekstra
Session: ePoster Display
706P - Real-world study assessing physician rationale for initiating first-line (1L) immuno-oncology (IO) therapy for patients with advanced urothelial cancer (aUC)
Presenter: Mayank Ajmera
Session: ePoster Display
707P - Treatment pattern and overall survival among patients with locally advanced or metastatic urothelial carcinoma: Results from a complete nationwide unselected real-world registry study in Denmark from 2010 to 2017
Presenter: Jorgen Bjerggaard Jensen
Session: ePoster Display
689P - Human leukocyte antigen (HLA) class I/II expression as a predictive biomarker for response to immune oncology (IO) therapy in metastatic clear-cell renal cell carcinoma (m-ccRCC)
Presenter: Lisa Kinget
Session: ePoster Display
595P - Correlation between genomic alterations and germline mutations in men with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Casilda Llacer Perez
Session: ePoster Display
596P - Impact of combined lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Blossom Mak
Session: ePoster Display
597P - A phase I dose-escalation study of LAE001 in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Dingwei Ye
Session: ePoster Display
598P - A phase Ib study of enzalutamide (Enza) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Jimmy Zhao
Session: ePoster Display